Cited by 292Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record, with a small difference in title or year; 50 of the 52 references it cites were found in a registry or an index.

Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials

Open access

Naci, Huseyin, Brugts, Jasper, Ades, Tony·2013·Circulation: Cardiovascular Quality and Outcomes

DOI 10.1161/circoutcomes.111.000071

Open this paper in CoChat — free account Open PDF

Abstract

Background—: Our objective was to estimate the comparative harms of individual statins using both placebo-controlled and active-comparator trials. Methods and Results—: We systematically reviewed randomized trials evaluating different statins in participants with and without cardiovascular disease. We performed random-effects pairwise and network meta-analyses to quantify the relative harms of individual statins. We included 55 two-armed placebo-controlled and 80 two- or multiarmed active-comparator trials including 246 955 individuals. According to pairwise meta-analyses, individual statins were not different than control in terms of myalgia, creatine kinase elevation, cancer, and discontinuations because of adverse events. Statins as a class resulted in significantly higher odds of diabetes mellitus (odds ratio, 1.09; 95% confidence interval, 1.02–1.16) and transaminase elevations (odds ratio, 1.51; 95% confidence interval, 1.24–1.84) compared with control. When individual statins were compared in network meta-analyses, there were numerous statistically detectable differences, favoring simvastatin and pravastatin. According to dose-level comparisons, individual statins resulted in higher odds of discontinuations with higher doses of atorvastatin and rosuvastatin. Similarly, higher doses of atorvasatin, fluvastatin, lovastatin, and simvastatin were associated with higher odds of transaminase elevations. Simvastatin at its highest doses was associated with creatine kinase elevations (odds ratio, 4.14; 95% credible interval, 1.08–16.24). Meta-regression analyses adjusting for study-level age at baseline, low-density lipoprotein cholesterol level, and publication year did not explain heterogeneity. There was no detectable inconsistency in the network. Conclusions—: As a class, adverse events associated with statin therapy are not common. Statins are not associated with cancer risk but do result in a higher odds of diabetes mellitus. Among individual statins, simvastatin and pravastatin seem safer and more tolerable than other statins.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circoutcomes.111.000071

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,172
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081

Flagged first, then by citations

Show all 52 references

2 of the 52 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Naci H Brugts J Fleurence R Ades AE. Comparative efficacy and safety of statins: a systematic review and mixed treatment comparison—final protocol. 2009; www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/HNaciProtocol.pdf. Accessed April 5 2013.

Sorted by citations

Items 201–291 of 291

Effects of LEP G2548A and LEPR Q223R Polymorphisms on Serum Lipids and Response to Simvastatin Treatment in Chinese Patients With Primary Hyperlipidemia
Li, K., Liu, Y., Venners, S. A., Hsu, Y., Jiang, S., Weinstock, J., Sun, Y., Wang, B., & Xu, X. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616638504 · Cited by 5
Emodin lows NPC1L1-mediated cholesterol absorption as an uncompetitive inhibitor
Meng, J., Xu, J., Yang, S., Liu, W., Zeng, J., Shi, L., Chang, J., Zhang, R., & Xing, D. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128974 · Cited by 5
Simvastatin: In Vitro Metabolic Profiling of a Potent Competitive HMG-CoA Reductase Inhibitor
Yin, W., Al-Wabli, R. I., Attwa, M. W., Rahman, A. F. M. M., & Kadi, A. A. (2022) · Separations · doi:10.3390/separations9120400 · Cited by 5
An analysis of psychotherapies delivered online and in person for patients with chronic pain: protocol for a systematic review and network meta-analysis.
Haugh, S., O’Connor, L. L., Slattery, B. W., Hanlon, M. L. D., Flynn, J., Quinn, S., Jennings, C., & McGuire, B. E. (2019) · HRB Open Research · doi:10.12688/hrbopenres.12953.1 · Cited by 6
Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations
O’Brien, T. J., Fenton, K., Sidahmed, A., Barbour, A., & Harralson, A. F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111226 · Cited by 4
Statin Intolerance: An Overview for Clinicians
Surma, S., Lewek, J., Penson, P. E., & Banach, M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_23 · Cited by 4
Searching the place of pitavastatin in the current treatment of patients with dyslipidemia
Barrios, V., Escobar, C., & Zamorano, J. L. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.844546 · Cited by 4
Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery
Chen, S., Wu, H., Yang, T., Li, B., Hu, Y., & Sun, H. (2019) · Cardiovascular Therapeutics · doi:10.1155/2019/1582183 · Cited by 4
Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
Saadati, H., Baradaran, H. R., Danaei, G., Ostovar, A., Hadaegh, F., Janani, L., Steyerberg, E. W., & Khalili, D. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01304-w · Cited by 4
Preventive cardiology for the aging population: how can we better design clinical trials of statins?
Wierzbicki, A. S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2302122 · Cited by 4
Retracted : LncRNA‐LET relieves hypoxia‐induced injury in H9c2 cells through regulation of miR‐138
Li, Y., Li, J., Zhang, P., Jiang, X., Pan, Z., Zheng, W., & Lin, H. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29146 · Cited by 4
Retracted
A Prospective Stratified Case-Cohort Study on Statins and Multiple Adverse Events in Japan
Ooba, N., Sato, T., Wakana, A., Orii, T., Kitamura, M., KOKAN, A., Kurata, H., Shimodozono, Y., Matsui, K., Yoshida, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096919 · Cited by 4
Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review
Ofori‐Asenso, R., Zomer, E., Curtis, A. J., Tonkin, A. M., Nelson, M. R., Gambhir, M., Liew, D., & Zoungas, S. (2017) · JMIR Research Protocols · doi:10.2196/resprot.7195 · Cited by 4
Statins for primary prevention of cardiovascular events in people with HIV: target trial and modelling study
Yebyo, H. G., Günthard, H. F., Rehfuess, E. A., Serra, N., Haile, S. R., Senn, O., Lucas, G. M., Langselius, O., Thorne, J. E., Marconi, V. C., et al. (2025) · BMJ Medicine · doi:10.1136/bmjmed-2024-001132 · Cited by 3
Nonfatal Outcomes in the Primary Prevention of Atherosclerotic Cardiovascular Disease
Czarny, M. J., Martin, S. S., Kohli, P., Metkus, T. S., & Blumenthal, R. S. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.000871 · Cited by 3
The rise of the statins and the burdening inefficiencies in liver monitoring
Al-Gailani, H., & Chadha, P. (2020) · BJGP Open · doi:10.3399/bjgpopen20x101066 · Cited by 3
Antioxidant and 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitory activities of some plant samples
Arslan, E. I. Ç., & Saçan, Ö. (2023) · Food and Health · doi:10.3153/fh23026 · Cited by 3
The problem of safety of lipid-lowering therapy
Zykov, M. V. (2019) · Kardiologiia · doi:10.18087/cardio.2505 · Cited by 3
Effect of Simvastatin on the Skeletal Muscles of Senile Male Albino Rats and Possible Protective Role of L- Carnitine. A Histological Study
Al‐Shahed, F. A. N., Mehanna, M. S., Allah, E. E.-D. A., & Al-Azab, H. (2019) · The Egyptian Journal of Histology · doi:10.21608/ejh.2019.17989.1184 · Cited by 3
Statin intolerance: diagnosis, treatment and alternative therapies
Naderi, S., & Cho, L. (2014) · Clinical Lipidology · doi:10.2217/clp.14.23 · Cited by 3
Trends and variations in outpatient coprescribing of simvastatin or atorvastatin with potentially interacting drugs in Thailand
Rattanachotphanit, T., Limwattananon, C., & Waleekhachonloet, O. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618820502 · Cited by 3
Colloidal Drug Delivery of Simvastatin for Prolonged Drug Release and Increased Bioavailability
Shaikh, S., & Bhagwat, G. (2023) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2023.00024 · Cited by 3
Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms
Bellows, B. K., Sainski-Nguyen, A. M., Olsen, C. J., Boklage, S., Charland, S. L., Mitchell, M. P., & Brixner, D. I. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.9.926 · Cited by 3
Statin withdrawal in people with dementia
McGuinness, B., Passmore, P., & Cardwell, C. R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012050 · Cited by 3
Natural products as HMG-CoA reductase inhibitors (statins) for the management of non-communicable diseases
Muhammad, R. N., Aborehab, N. M., Aly, S. H., Nasr, N. N., Hindam, M. O., Mustafa, A. M., Faheem, S. A., Fawzy, M. H., Fetoh, M. E. A., El‐Dessouki, A. M., et al. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02069-2 · Cited by 5
Associations between Suspected Adverse Drug Reactions of HMG-CoA Reductase Inhibitors and Polypharmacology Using a National Registry Approach
Yousaf, H., & Jones, A. M. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3030016 · Cited by 2
Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC)
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Statin-Induced Hyper-Acute Reversible Liver Failure: A Case Report
Alturki, A., Alqahtani, K. S., Alnasser, D. A., AlTalha, M. M., & Alhamdan, A. S. (2026) · Cureus · doi:10.7759/cureus.103591 · Cited by 2
GINGER ETHANOLIC EXTRACT, GINGER OIL OR RICE BRAN OIL INDUCED HEPATOPROTECTIVE EFFECT AGAINST FATTY LIVER IN RATS
Allah, H. A. A. A. A., El-wahab, B. A., Ramadan, K. M. A., & Ali, S. (2018) · Arab Universities Journal of Agricultural Sciences · doi:10.21608/ajs.2018.28366 · Cited by 2
Statin-Induced Myopathy
Sychev, D. A., Оstroumova, Т. М., Ostroumova, O. D., Кочетков, А. И., Владимировна, Б. С., & Mironova, E. V. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-3-252-270 · Cited by 2
Pharmacology of statins: A brief overview
Patel, B. (2014) · Nurse Prescribing · doi:10.12968/npre.2014.12.9.451 · Cited by 2
Prioritizing health outcomes in a limited world
Qureshi, N., Minhas, R., & Wierzbicki, A. S. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000170 · Cited by 2
Statins Cardiovascular Benefits Outweigh their Diabetogenicity: A Direct Comparison between Number Needed to Treat and Number Needed to Harm
Shimoyama, S. (2015) · Advances in Pharmacoepidemiology & Drug Safety · doi:10.4172/2167-1052.1000185 · Cited by 2
The challenges of proprotein convertase subtilisin–kexin-9 inhibitors for lipid guidelines and models of care
Wierzbicki, A. S. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000453 · Cited by 2
Analysis of Safety Issues of Using Statins in Patients with Diabetes and Hypothyroidism
Arkhipov, V. V., Gorodetskaya, G. I., Демидова, О. А., Alexandrova, T. V., & Alexandrov, A. A. (2019) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2019-7-4-163-175 · Cited by 2
Potential Content of Karamunting (Rhodomyrtus tomentosa) in Binding With HMG-CoA Reductase
Nastiti, K., & Hadi, S. (2021) · Journal Pharmaceutical Care and Sciences · doi:10.33859/jpcs.v2i1.76 · Cited by 2
Yellow Yeast Rice Prepared Using Aspergillus terreus DSMK01 Lowers Cholesterol Levels by Stimulating Bile Salt Export Pump in Subjects with Mild‐to‐Moderate Hypercholesterolemia: A Randomized Controlled Trial
Kang, S., Lee, E., Lee, H., Hwang, G., Lee, J., Kim, J. W., Oh, B., Kim, J. Y., & Kwon, O. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100704 · Cited by 2
Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund
Bobrowska, B., Krawczyk‐Ożóg, A., Bartuś, S., & Rajtar-Salwa, R. (2022) · Advances in Interventional Cardiology · doi:10.5114/aic.2022.118533 · Cited by 2
From guidelines to decision aids and adherence supports: Insights from the process of evidence translation
Sheridan, S. (2023) · Patient Education and Counseling · doi:10.1016/j.pec.2023.107806 · Cited by 2
The Relationship Between Suspected Adverse Drug Reactions Of HMG-Coa Reductase Inhibitors And Polypharmacology Using A National Registry ApproachPreprint
Yousaf, H., & Jones, A. M. (2024) · medRxiv · doi:10.1101/2024.04.02.24305224 · Cited by 2
Which statin has the lowest risk of myalgia?
Pejic, R. N. (2020) · Evidence-Based Practice · doi:10.1097/ebp.0000000000000736 · Cited by 1
High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study
Chiusolo, S., Masini, G., Zywicki, V., Bort, I. R., Malloggi, L., Gargani, L., Palagi, C., & Caterina, R. D. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134140 · Cited by 1
Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC)
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 2
The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts’ Proposal
Surma, S., Barylski, M., Schmieder, R. E., Borghi, C., Mancia, G., Lip, G. Y. H., & Filipiak, K. J. (2026) · European Cardiology Review · doi:10.15420/ecr.2026.08 · Cited by 2
Therapeutic Options: Lifestyle Measures and Pharmacological Approaches
Wilkinson, I. B., & King, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-14556-3_29 · Cited by 1
The simultaneous systematic analysis approach for personalized management of cardiovascular diseases
Marcus-Kalish, M., & Meiri, H. (2014) · European Journal of Nanomedicine · doi:10.1515/ejnm-2014-0008 · Cited by 1
Characterization of diabetes risk factors in patients prescribed chronic statin therapy
King, W. M., Saseen, J. J., & Anderson, S. L. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314530460 · Cited by 1
Place des statines chez le sujet âgé
Hammami, R., Jdidi, J., Triki, F., Hammami, B., Abid, L., Ksouda, K., Hammami, S., Abid, D., Hentati, M., & Kammoun, S. (2015) · Therapies · doi:10.2515/therapie/2015057 · Cited by 1
Medikamentöse Senkung des LDL-Cholesterins
Barthelmes, J., & Sudano, I. (2017) · Praxis · doi:10.1024/1661-8157/a002759 · Cited by 1
CCS Guidelines and Position Statements Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia
Genest, J. J., Hegele, R. A., Bergeron, J., Brophy, J. M., Carpentier, A. C., Couture, P., Davignon, J., Dufour, R., Frohlich, J. J., Gaudet, D., et al. (2014) · Cited by 1
A Randomized Trial of Alerting to Hypocholesterolemia Results of the Low Indexes of Metabolism Intervention Trial-C (LIMIT-C)
Tsabar, N., Press, Y., Rotman, J., Klein, B., Grossman, Y., Vainshtein‐Tal, M., & Eilat‐Tsanani, S. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.08.018 · Cited by 1
Circulation: Cardiovascular Quality and Outcomes
Editors, T. (2014) · Circulation · doi:10.1161/circulationaha.113.008404 · Cited by 1
Mitochondrial complex III activity: from invasive muscle biopsies to patient-friendly buccal swab analysis
Somers, T., Allard, N. A. E., Siddiqi, S., Janssen, M. C. M., Hopman, M. T. E., Morshuis, W. J., Rüssel, F. G. M., Timmers, S., & Schirris, T. J. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-36741-w · Cited by 1
Anti-atherogenic properties of Plectranthus glandulosus Hook. F. (Lamiaceae) leaves through lipid profile regulation, oxidative stress reduction, and aorta media thickening attenuation in high-fat diet-fed Sprague-Dawley rats
Zouheira, D., Kajal, A., Nchouwet, M. L., Kamani, S. L. P., Yamthé, L. R. T., Agbor, G. A., Ngnokam, S. L. W., & Singh, R. (2025) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2025.2476644 · Cited by 1
PCSK9 Inhibitors
Mueller, Z. T., Craddock, K. E., Pitlick, J. M., & Crannage, A. J. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516653970 · Cited by 1
The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence
Li, X., Sun, S., Xu, X., Zhao, Z., & Li, W. (2018) · Drug Research · doi:10.1055/a-0677-2944 · Cited by 1
Investigating the Incidence, Diagnosis, Prevention and Management of Statin-Induced Adverse Effects
Hasani, R. A., Matrafi, E. A., Harbi, R. A., Hazmi, R. A., Hazmi, S. A., Jumana, S., Elashmony, S. M., Fairaq, A., & Hindi, Y. A. (2021) · International Journal of Life Science and Pharma Research · doi:10.22376/ijpbs/lpr.2021.11.2.p153-158 · Cited by 1
Unanswered questions about higher potency statins and the risk of new diabetes
Brugts, J. J. (2014) · BMJ · doi:10.1136/bmj.g4876 · Cited by 1
Self-citation
La guía europea de dislipemia. Fortalezas y debilidades
Alegría-Ezquerra, E., Alegría‐Barrero, E., & Alegría-Barrero, A. (2015) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(15)70119-6
Author's reply to Phillips and Brugts
Dormuth, C. R. (2014) · BMJ · doi:10.1136/bmj.g4890
Srce i krvni Sudovi
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Generic versus brand-name cardiovascular drugs: a remarkable update
Flacco, M. E., Fragassi, G., & Manzoli, L. (2022) · Epidemiology Biostatistics and Public Health · doi:10.2427/11651
Ischaemic heart disease - risk assessment, diagnosis, and secondary preventive treatment in primary care, with special reference to the relevance of exercise ECG
Nilsson, G. H. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Drug Safety: All Statins Are Not Created Equal
Finn, K. M., & Dressler, D. D. (2013) · Journal watch · doi:10.1056/nejm-jw.na32150
Costo-efectividad de las estatinas para el tratamiento de dislipidemia en Colombia Cost-effectiveness of statins for the treatment of dyslipidemia in Colombia
Rosselli, D., Castaño, N., & Peña, Á. A. G. (2015)
Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins
Ma, B. (2014)
The Effects of Hydroalcoholic Borage Extract on Serum Lipid Profile in Mice and Comparison with Lovastatin
Cheraghi, J., کیمیاگر, م., & وریان, ع. ا. پ. (2016) · journal of ilam university of medical sciences · doi:10.18869/acadpub.sjimu.24.3.1
Effect of low density lipoproteins on the progression of chronic lymphocytic leukemia
McCaw, L. (2016) · TSpace (University of Toronto)
Infográficos para decisão compartilhada no uso de estatinas em paciente de alto risco cardiovascular
Pinto, F. K. M. S., & de Oliveira, J. C. (2019) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc14(41)1809
Medical Management of Atherosclerotic Carotid Disease
Doud, A. J., & Tirschwell, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-41138-1_5
References
Dias, S., Ades, A. E., Welton, N. J., Jansen, J. P., & Sutton, A. J. (2018) · Wiley eBooks · doi:10.1002/9781118951651.refs
A comprehensive assessment of statin discontinuation among patients who concurrently initiate statins and CYP3A4‐inhibitor drugs; a multistate transition model
Donneyong, M. M., Zhu, Y., Zhang, P., Zhang, P., Li, Y., Hunold, K. M., Chiang, C., Unroe, K. T., Caterino, J. M., & Li, L. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15373
Análise de aspectos sociodemográficos e clinicopatológicos em pacientes com Doença Arterial Coronariana e controles saudáveis
Crepaldi, G. L. D. S., Gomes, N. S., Xavier, I. M., Miranda, B. M., & Crepaldi, A. A. D. S. (2023) · Brazilian Journal of Development · doi:10.34117/bjdv9n1-352
Advanced therapeutics for targeting atherosclerosis
Bhunia, S. S., & Debnath, U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99988-5.00005-x
Evaluation of CPK (Creatinine Phosphokinase) in Hypertensive Patients used either Statin and/or Ezetimibe
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.04.029
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.135
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention
Kim, C. J., Godfrey, K., Patnaik, S., & Mehran, R. (2024) · Vessel Plus · doi:10.20517/2574-1209.2023.136
Identification of endophenotypes supporting outcome prediction in hemodialysis patients based on mechanistic markers of statin treatment
Leierer, J., Salib, M., Evgeniou, M., Rossignol, P., Massy, Z. A., Kratochwill, K., Mayer, G. J., Fellström, B., Girerd, N., Zannad, F. M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30709
Perspective Chapter: Sex Differences during Statin Therapy in Patients with Elevated Risk of Cardiovascular Disease and Cancer
Ábel, T., & Csobod, É. C. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010879
Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Society of Atherosclerosis (NSFA) and the French Society of Cardiology (SFC)
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Additional file 1 of Association of statin use and increase in lipoprotein(a): a real-world database research
Feng, T., Li, Y., Xue, X., Yang, W., Li, Q., Huang, Y., Zhu, T., Wang, J., Xu, L., Li, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26601370
Additional file 3 of Association of statin use and increase in lipoprotein(a): a real-world database research
Feng, T., Li, Y., Xue, X., Yang, W., Li, Q., Huang, Y., Zhu, T., Wang, J., Xu, L., Li, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26601376
Additional file 1 of Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
Yebyo, H. G., Zappacosta, S., Aschmann, H. E., Haile, S. R., & Puhan, M. A. (2020) · Figshare · doi:10.6084/m9.figshare.12972022
Additional file 1 of Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
Saadati, H., Baradaran, H. R., Danaei, G., Ostovar, A., Hadaegh, F., Janani, L., Steyerberg, E. W., & Khalili, D. (2020) · Figshare · doi:10.6084/m9.figshare.13191903
Additional file 2 of Association of statin use and increase in lipoprotein(a): a real-world database research
Feng, T., Li, Y., Xue, X., Yang, W., Li, Q., Huang, Y., Zhu, T., Wang, J., Xu, L., Li, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26601373
Mechanistic insights into the cholesterol-lowering activity of γ-oryzanol components
Cuccioloni, M., Juricic, H., Bonfili, L., Liu, Z., Abate, G., Uberti, D. L., Angeletti, M., Eleuteri, A. M., & Cecarini, V. (2026) · Food & Function · doi:10.1039/d5fo03394b
Long‐Term Adherence and Drug Utilisation Patterns Among New Users of Anti‐Hyperlipidemic Monotherapy: Development of a Risk Prediction Model
Li, X., Hak, E., Bos, J., Schuiling‐Veninga, C. C. M., & Mubarik, S. (2026) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70380
A Clinical Review on HMG-CoA Reductase Inhibitors (Statins)-induced Hyperglycemia and New-onset Diabetes Mellitus (NODM)
Maideen, N. M. P., Jumale, A. H., Albasti, A. K., Kadir, D. A. A., Alkhawalda, M. Y., Shokr, A. F., & Canani, M. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x429107251202110301
The impact of concomitant use of rosuvastatin or atorvastatin plus clopidogrel on the platelet inhibition and clinical outcomes in acute large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the ROCATIS-1 trial
Zeinhom, M. G., Ismaiel, M. D., Khalil, M. F. E., Elmesallami, A. G., Khalil, G. A. E. W., Akl, A. Z. O., Georgy, S. S., Abbas, A. A., Kerolos, Y. S. S., Abdeldayem, S. M., et al. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864261483407
Atorvastatin potentiates the efficacy of gemcitabine in diabetic pancreatic cancer via remodeling the tumor immune microenvironment and attenuating vascular endothelial
Li, L., He, Y., Peikai, T., Chen, J., Gong, X., & Li, X. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag102
Alteraciones musculares inducidas por fármacos
Mora, R. M., & Bellsolà, M. G. (2015) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2015.02.024

Authors: Naci, H., Brugts, J., & Ades, T.
Affiliations: Erasmus MC (NL)
From the LSE Health, London School of Economics and Political Science, London, United Kingdom (H.N.); Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands (J.B.); and .School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom (T.A.).
ORCID: Naci, Huseyin
Brugts, Jasper
Venue: Circulation: Cardiovascular Quality and Outcomes
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-07
Volume: 6
Issue: 4
Pages: 390-399
ISSN: 1941-7705 (ISSN-L)
1941-7713
DOI: 10.1161/circoutcomes.111.000071
OpenAlex: W2160313369
Cited by: 292
References: 52
Citations by year: 2026: 10 · 2025: 8 · 2024: 17 · 2023: 14 · 2022: 15 · 2021: 20 · 2020: 26 · 2019: 31 · 2018: 23 · 2017: 21 · 2016: 36 · 2015: 24 · 2014: 38 · 2013: 8
FWCI: 34.80
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation Cardiovascular Quality and Outcomes (publishedVersion)
PubMed (publishedVersion)
London School of Economics and Political Science Research Online (London School of Economics and Political Science) (acceptedVersion)
London School of Economics and Political Science Research Online (London School of Economics and Political Science) (submittedVersion)
Funders: McMaster University
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: statins, statin safety, tolerability, diabetes mellitus, transaminase elevation, creatine kinase elevation, myalgia, cancer risk, simvastatin, pravastatin, dose-response relationship, cardiovascular disease
MeSH terms: Cardiovascular Diseases, Dose-Response Relationship, Drug, Humans, Lipids, Risk Factors, Biomarkers, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks